Ren Yong-Bo, Qi Yan-Xiu, Su Xing-Jie, Luan He-Qun, Sun Qi
Department of Ophthalmology, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Medicine (Baltimore). 2019 Jul;98(29):e15404. doi: 10.1097/MD.0000000000015404.
This study retrospectively evaluated the effect of lutein supplement (LS) on patients with non-proliferative diabetic retinopathy (NPDR).A total of 72 patients with NPDR were included in this study. All patients received Zeaxanthin during the study period. In addition, 36 patients also received LS and were assigned to the treatment group, while the other 36 patients did not receive LS and were assigned to the control group. All patients were treated for a total of 4 months. The endpoints included visual acuity (VA), contrast sensitivity (CS), and glare sensitivity (GS). In addition, any adverse events were also assessed. All endpoints were measured before and after 4-month treatment.Before treatment, there were no significant differences in VA (P = .75), CS (P = .71), and GS (P = .73) between two groups. After 4-month treatment, there were still no significant differences in all endpoints of VA (P = .66), CS (P = .58), and GS (P = .61) between two groups. No adverse events were recorded in either group.The results of this retrospective study showed that LS may not benefit for patients with NPDR after 4-month treatment. More high quality randomized controlled trials should still be needed to warrant the results of this study.
本研究回顾性评估了叶黄素补充剂（LS）对非增殖性糖尿病视网膜病变（NPDR）患者的影响。本研究共纳入72例NPDR患者。在研究期间，所有患者均接受了玉米黄质。此外，36例患者还接受了LS并被分配到治疗组，而另外36例患者未接受LS并被分配到对照组。所有患者共治疗4个月。终点指标包括视力（VA）、对比敏感度（CS）和眩光敏感度（GS）。此外，还评估了所有不良事件。所有终点指标均在4个月治疗前后进行测量。治疗前，两组之间的VA（P = 0.75）、CS（P = 0.71）和GS（P = 0.73）无显著差异。4个月治疗后，两组之间的VA（P = 0.66）、CS（P = 0.58）和GS（P = 0.61）的所有终点指标仍无显著差异。两组均未记录到不良事件。这项回顾性研究的结果表明，4个月治疗后，LS可能对NPDR患者没有益处。仍需要更多高质量的随机对照试验来证实本研究的结果。
